- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07353255
Fibroscopio frente a videolaringoscopio para intubación nasotraqueal
Fibroscopio Flexible Versus Videolaringoscopio para Intubación Nasotraqueal - Una Comparación Aleatorizada
Los pacientes que se someten a cirugía bajo anestesia general requieren la inserción de un tubo de respiración para mantener las vías respiratorias abiertas. La técnica de insertar un tubo de respiración a través de la nariz hacia la tráquea (vía respiratoria) se conoce como intubación nasotraqueal. Este es el acceso ideal para procedimientos quirúrgicos realizados dentro de la boca, como extracciones dentales complejas y operaciones en la mandíbula.
Tradicionalmente, el tubo de respiración se inserta inicialmente a ciegas en la cavidad nasal, luego se utiliza un videolaringoscopio (un dispositivo con cámara) o un laringoscopio directo para visualizar y guiar el paso del tubo hacia la tráquea. Este enfoque puede asociarse con dificultades para pasar el tubo y tiene una alta incidencia de traumatismo nasal y hemorragia nasal. Un fibroscopio flexible (dispositivo de cámara flexible) con un tubo traqueal precargado se pasa primero a través de la fosa nasal bajo visión, se avanza suavemente a través del conducto nasal y luego hacia la tráquea. Una vez colocado correctamente en la tráquea, el tubo de respiración se desliza sobre él. Este procedimiento permite visualizar el conducto nasal y elegir la fosa nasal más permeable, lo que probablemente reduce el riesgo de hemorragia nasal en comparación con el paso a ciegas del tubo a través de la nariz. Un videolaringoscopio tiene una cámara en la pala que proyecta la imagen en una pantalla de monitor. Como es un dispositivo rígido, solo puede insertarse a través de la cavidad oral y permite el avance del tubo hacia la tráquea. Ambas técnicas se utilizan actualmente en la práctica clínica. Sin embargo, no hay estudios que informen a los anestesiólogos si existen diferencias en la incidencia de hemorragia nasal.
Deseamos realizar una comparación aleatorizada entre el fibroscopio flexible y el videolaringoscopio en términos de reducción del riesgo y la gravedad de la hemorragia nasal.
Se invitará a participar en el estudio a pacientes mayores de 18 años, que se presenten para procedimientos quirúrgicos electivos y requieran anestesia general e intubación nasal. Nuestro objetivo es reclutar 200 participantes (consulte la sección de tamaño de muestra) para observar diferencias significativas en la incidencia de hemorragia nasal.
Los pacientes que sean elegibles y den su consentimiento para participar en el estudio serán asignados aleatoriamente al grupo de fibroscopio flexible o al de videolaringoscopio. En el momento de la intubación nasotraqueal, se registrarán la suavidad de la intubación nasal, la gravedad del sangrado nasal y el tiempo necesario para completar la intubación traqueal. Cinco minutos después de la intubación, el cirujano que realiza la cirugía (ciego a la técnica de intubación) examinará la cavidad oral en busca de sangrado. Esto se clasificará utilizando una puntuación estandarizada de sangrado nasal. Todos los pacientes serán visitados en el período postoperatorio para verificar cualquier hemorragia nasal continua y malestar nasal. Los detalles del paciente que se recopilarán incluyen género, edad, peso, altura, índice de masa corporal y parámetros de evaluación de las vías respiratorias. No se requieren otros datos personales.
Este estudio tiene como objetivo ver si el uso del fibroscopio flexible reduce el sangrado nasal y mejora la seguridad del paciente. Si no hay diferencia, puede proporcionar tranquilidad en el uso continuo de la videolaringoscopia para la intubación nasal.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Introduction
The technique of inserting a tracheal tube through the nasal passage into the trachea (airway) is known as nasotracheal intubation. This is the preferred airway for surgical procedures performed in and around oral cavity including dental procedures. Traditionally, the tracheal tube is initially inserted blindly into the nasal cavity. A laryngoscope is then used to visualise and help guide the passage of the tube into the trachea. This approach can be associated with difficulty passing the tube and a high incidence of nasal trauma [1, 2], as the nasal passages can be narrow and demonstrate inter-individual anatomic variability.
Various approaches have been described in the literature to reduce nasal trauma including warming the tube [3], applying water-based lubricants and preparing the nasopharynx with progressive dilation and/or a topical vasoconstrictors [4]. There have been randomised studies using curve-tipped suction catheters [2], and bougies [1,5] showing reduced incidence of nasal trauma as compared to blind passage of the tube through the nose. However, as these devices are blindly inserted through the nasal passage, the device itself can cause some degree of trauma.
The investigators hypothesise that the use of the flexible fibrescope could reduce nasal trauma and bleeding whilst improving first time intubation success rates, when compared to video laryngoscope-assisted nasal intubation. Using a fiberscope allows for an assessment of the patency of the nasal passages and visualisation of the path the tube will take through the nasopharynx.
In current practice, both flexible fibrescopes and video laryngoscopes are routinely used for tracheal intubation. However, with video laryngoscopy during nasal intubation, insertion of tube through the nasal passage is blind. Therefore, some practitioners prefer using a fiberscope for nasal intubation. Clinicians are uncertain as to which is the best approach. To our knowledge, previous studies have not utilised flexible fibrescopes to eliminate blind insertion of the tube in the nostril. Comparing the efficacy of a flexible fibrescope with a tracheal tube railroaded over it to a video laryngoscope for nasotracheal intubation could inform airway practitioners on their choice of technique to improve success and minimise bleeding risk.
Methods
On arrival to theatre, following a standard WHO surgical safety check list and application of routine monitoring, patients will be randomly allocated to either flexible fibrescope or video laryngoscope to facilitate nasotracheal intubation. All patients will receive decongestant nasal spray of 5% lidocaine with 0.5% phenylephrine 1 ml in each nostril.
Both a flexible fiberscope and a video laryngoscope will be available in the anaesthetic room prior to revelation of the group.
All other aspects of patient care outside of the randomisation to fibrescope or video laryngoscopy for nasotracheal intubation will be conducted in accordance with routine clinical practice and local guidelines.
For patients randomised to the video laryngoscope, laryngoscopy will be performed using the video laryngoscope: Mcgrath ™ MAC video laryngoscope (Medtronic Plc, Galway Ireland). A lubricated 6.0 mm ID tube: Polar™ Preformed Tracheal tube, North Nasal Profile™ (Smiths Medical ASD, Inc, Minneapolis, USA) will be inserted through the most patent nostril (as identified during preoperative visit) and advanced until it reaches the posterior nares. It will be then advanced through the vocal cords into the trachea under video guidance. If there was any hold-up immediately after passing the tube through the nostrils, the tube will be gently rotated to allow passage through the nasopharynx. If there is any impingement at the level of arytenoids, the tube will be withdrawn slightly, rotated anticlockwise and then advanced.
For patients randomised to the fiberscope, the same tube type will be loaded on the 4mm fibrescope: Flex. Intubation Video Endoscope 4 x 65 - model 11302BDX (Karl Stortz Tuttlingen, Germany) prior to beginning intubation. The fibrescope will then be inserted into the most patent nostril. If this nostril is deemed to be adequate by the operator, the procedure will continue, otherwise the other nostril will be assessed and the most optimal nostril will be chosen for intubation. The fibrescope will be advanced through the nasopharynx and into the trachea. At this point the tube will be advanced over the fiberscope from the trachea.
Correct placement of the tube will be confirmed using end tidal CO2 and once nasotracheal intubation is completed the rest of the anaesthetic management will proceed as planned by the lead anaesthetist.
During nasotracheal intubation the data collected will include severity of nasal trauma on a 4 point scale, smoothness of nasal intubation on a 4 point scale , laryngoscopy time (from insertion of laryngoscope in the mouth to visualize the vocal cords or from insertion of fiberscope in the nostril to visualise the vocal cords), intubation time (time from insertion of fiberscope or video laryngoscope till first capnography trace) and first attempt success rate (% of intubations succeeded in first attempt), number of intubation attempts and any additional manoeuvres required (external pressure on thyroid cartilage, tube rotation, tube impingement).
Follow-up assessments
Patients will be reviewed in the first 3 to 24 hours whilst they are in the hospital, as apart a standard postoperative visit, where an assessment of patient-centred secondary outcomes will be made. No further follow up is required for this study. If any patients report continuing nasal bleed in the postoperative period, a maxillofacial surgeon will be requested to review the patient for further management and any outcome data may be collected up to 72 hours.
Consent
Participants will be given adequate time to read and understand the patient information leaflet. Once they have read the information, any questions will be answered. If they agree for the study, they will be asked to complete the consent form. The consent will be obtained by chief investigator, principal investigator or one of the research team members delegated and supervised by the investigators.
Sample size
Sample size is based on the primary outcome of incidence of nasal bleeding. A previous study of video laryngoscope assisted nasotracheal intubation reported a rate of bleeding detected in the posterior pharynx of 68% (Abrons 2017). A relative reduction in 33% is considered clinically significant. To detect this treatment difference at a significant level of 5% and power of 90%, a total sample of 186 patients is required. To account for failure and loss of follow up, the investigators will recruit a total of 200 patients.
Randomisation Methodology
Participants will be randomised using a paper randomisation list that will be provided to the UHCW Research and Development (R&D) department, independent from the rest of the study team. The randomisation list will be generated by the study statistician prior to recruitment starting. The method of permuted random blocks will be utilised, with varying block sizes used.
Blinding
It will not be possible to blind the investigator to the type of device used. However, 5 minutes after completion of intubation, the operating surgeon (who is blinded to the technique of intubation) will examine the oropharynx and record the bleeding. At the time of intubation, the investigator will record the bleeding as seen on video laryngoscope or fiberscope monitor screen.
Assessment and management of risk
For this study, patients requiring general anaesthesia and nasotracheal intubation for elective surgical procedures will be recruited. The flexible fibrescope and video laryngoscope selected for this study are currently used in routine clinical practice as intubation aids. In the event of any unanticipated difficulty with intubation, the lead anaesthetist will follow the Difficult Airway Society guidelines and data collection will stop at this point.
The lead anaesthetist is free to choose different airway equipment to those specified by the study if they feel that this would be clinically appropriate. The investigators do not anticipate any additional risks to the study participants. During the procedure of airway management, all patients will be closely monitored as specified by 'Association of Anaesthetists' standards of monitoring during anaesthesia. This includes peripheral oxygen saturation, end tidal oxygen, depth of anaesthesia and end-tidal CO2, ECG and blood pressure.
References
- Abrons RO, Zimmerman MB, El-Hattab YMS. Nasotracheal intubation over a bougie vs. non-bougieintubation: a prospective randomised, controlled trial in older children and adults usingvideolaryngoscopy. Anaesthesia 2017; 72: 1491-500.
- Morimoto Y, Sugimura M, Hirose Y, Taki K, Niwa H. Nasotra- cheal intubation under curve-tipped suction catheter guidance reduces epistaxis. Canadian Journal of Anesthesia 2006; 53: 295-8
- Kim YC, Lee SH, Noh GJ, et al. Thermosoftening treatment of the nasotracheal tube before intubation can reduce epistaxis and nasal damage. Anesthesia and Analgesia 2000; 91: 698- 701.
- El-Seify ZA, Khattab AM, Shaaban AA, Metwalli OS, Hassan HE, Ajjoub LF. Xylometazoline pretreatment reduces nasotra- cheal intubation-related epistaxis in paediatric dental surgery. British Journal of Anaesthesia 2010; 105: 501-5.
- Bansal T, Singhal S, Dhingra K. A study to evaluate nasotracheal intubation using Airtraq laryngoscope with a bougie and without a bougie. Indian J Anaesth 2022;66:757-62.
- Collins SR, Blank RS. Fiberoptic intubation: an overview and update. Respir Care. 2014 Jun;59(6):865-78; discussion 878-80. doi: 10.4187/respcare.03012. PMID: 24891196.
- Hansel, J., Roger, A.M., et al. (2022) Videolaryngoscopy versus direct laryngoscopy for adults undergoing tracheal intubation, Cochrane Database of Systematic Reviews, 4(4), CD011136. Available at https://pubmed.ncbi.nlm.nih.gov/35373840/ (Accessed 5 July 2023)
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Charles Pairaudeau, FRCA
- Número de teléfono: +44719121363
- Correo electrónico: Charles.Pairaudeau2@uhcw.nhs.uk
Copia de seguridad de contactos de estudio
- Nombre: Maria Turslove
- Número de teléfono: +442476966053
- Correo electrónico: ResearchSponsorship@uhcw.nhs.uk
Ubicaciones de estudio
-
-
West Midlands
-
Coventry, West Midlands, Reino Unido, CV2 2DX
- Reclutamiento
- University Hospital Coventry
-
Contacto:
- Charles F Pairaudeau
- Número de teléfono: +442476 965874
- Correo electrónico: charles.pairaudeau2@uhcw.nhs.uk
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Criterios de inclusión:
Se invitará a participar en el estudio a pacientes de 18 años o más, que acudan para procedimientos quirúrgicos electivos y requieran anestesia general e intubación nasal.
Criterios de exclusión:
- Pacientes que no deseen participar o no den su consentimiento.
- Pacientes incapaces de dar consentimiento por escrito.
- Estado físico del paciente ASA 4 y 5.
- Pacientes que se considere que requieren intubación despierta.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Fibroscopio Flexible
Asignado aleatoriamente para intubación mediante fibroscopio flexible
|
Intubación de la tráquea por vía nasal con Fibroscopio (11302BDX Flex.
Intubación Video Endoscopio 4 x 65 Karl Storz)
|
|
Comparador activo: Videolaringoscopio
asignado aleatoriamente para intubación con videolaringoscopio
|
Intubación de la tráquea por vía nasal utilizando videolaringoscopio (301-000-000 McGRATH™ con hoja Mac)
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Nasal trauma score
Periodo de tiempo: 5 minutes from nasotracheal intubation
|
a score of 0 to 3 will be provided no bleeding, moderate bleeding, or severe bleeding
|
5 minutes from nasotracheal intubation
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
nasal intubation smoothness score
Periodo de tiempo: During nasotracheal Intubation
|
A score of 0 to 3 being given; smooth insertion (0), slight resistance, insertion with great resistance and not possible to insert requiring change of nostril
|
During nasotracheal Intubation
|
|
Total intubation time
Periodo de tiempo: During nasotracheal intubation
|
time in seconds from insertion of fiberscope or video laryngoscope till first capnography trace
|
During nasotracheal intubation
|
|
Laryngoscopy time
Periodo de tiempo: During nasotracheal intubation
|
time in seconds from insertion of laryngoscope in the mouth to visualize the vocal cords or from insertion of fiberscope in the nostril to visualise the vocal cords
|
During nasotracheal intubation
|
|
incidence of post operative sore throat
Periodo de tiempo: Between 3 to 24 hours after intervention (nasotracheal intubation)
|
Number of patients having soret throat in the post operative period
|
Between 3 to 24 hours after intervention (nasotracheal intubation)
|
|
incidence of postoperative nasal discomfort
Periodo de tiempo: Between 3 to 24 hours after intervention (nasotracheal intubation)
|
number of patients having nasal discomfort in the postoperative period
|
Between 3 to 24 hours after intervention (nasotracheal intubation)
|
|
Incidence of post operative nasal bleeding or blood stained discharge
Periodo de tiempo: Between 3 to 24 hours after intervention (nasotracheal intubation)
|
number of patients having nasal discomfort in the postoperative period
|
Between 3 to 24 hours after intervention (nasotracheal intubation)
|
Colaboradores e Investigadores
Investigadores
- Director de estudio: Cyprian Mendonca, University Hopsitals Coventry & Warwickshire NHS Trust
Publicaciones y enlaces útiles
Publicaciones Generales
- Morimoto Y, Sugimura M, Hirose Y, Taki K, Niwa H. Nasotracheal intubation under curve-tipped suction catheter guidance reduces epistaxis. Can J Anaesth. 2006 Mar;53(3):295-8. doi: 10.1007/BF03022218.
- Kim YC, Lee SH, Noh GJ, Cho SY, Yeom JH, Shin WJ, Lee DH, Ryu JS, Park YS, Cha KJ, Lee SC. Thermosoftening treatment of the nasotracheal tube before intubation can reduce epistaxis and nasal damage. Anesth Analg. 2000 Sep;91(3):698-701. doi: 10.1097/00000539-200009000-00038.
- Collins SR, Blank RS. Fiberoptic intubation: an overview and update. Respir Care. 2014 Jun;59(6):865-78; discussion 878-80. doi: 10.4187/respcare.03012.
- Bansal T, Singhal S, Dhingra K. A study to evaluate nasotracheal intubation using Airtraq laryngoscope with a bougie and without a bougie. Indian J Anaesth. 2022 Nov;66(11):757-762. doi: 10.4103/ija.ija_466_22. Epub 2022 Nov 18.
- El-Seify ZA, Khattab AM, Shaaban AA, Metwalli OS, Hassan HE, Ajjoub LF. Xylometazoline pretreatment reduces nasotracheal intubation-related epistaxis in paediatric dental surgery. Br J Anaesth. 2010 Oct;105(4):501-5. doi: 10.1093/bja/aeq205. Epub 2010 Aug 3.
- Abrons RO, Zimmerman MB, El-Hattab YMS. Nasotracheal intubation over a bougie vs. non-bougie intubation: a prospective randomised, controlled trial in older children and adults using videolaryngoscopy. Anaesthesia. 2017 Dec;72(12):1491-1500. doi: 10.1111/anae.14029. Epub 2017 Sep 15.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- 343162
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .